Azeliragon(PF-04494700,TTP488)

Name	1-PropanaMine, 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-iMidazol-4-yl]phenoxy]-N,N-diethyl-
Synonyms	Azeliragon AZELIRAGON Azeliragon (TTP488) Azeliragon(PF-04494700,TTP488) 3--4--2-Butyl-1--4--4-chlorphenoxy-phenyl--1H-imidazol-4-yl-phenoxy--N-N-diethylpropan-1-amin 3-(4-(2-butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethylpropan-1-amine N-[3-[4-[2-Butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]propyl]-N,N-diethylamine 1-PropanaMine, 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-iMidazol-4-yl]phenoxy]-N,N-diethyl-
CAS	603148-36-3

Molecular Formula	C32H38ClN3O2
Molar Mass	532.12
Density	1.11±0.1 g/cm3(Predicted)
Boling Point	667.7±65.0 °C(Predicted)
pKa	10.16±0.25(Predicted)
Storage Condition	Room Temprature
In vivo study	In an animal model of Alzheimer's disease (tgapp sweet/London), azerraton can reduce the deposition of Aβ plaque, reduce the total concentration of Aβ and increase the level of Aβ in plasma, lowering of sAPPβ to increase sappα levels, reducing inflammatory cytokines, slowing cognitive decline processes, and improving cerebral blood flow.